Literature DB >> 8254754

Interactions of normal and mutant vesicular stomatitis virus matrix proteins with the plasma membrane and nucleocapsids.

L D Chong1, J K Rose.   

Abstract

We demonstrated recently that a fraction of the matrix (M) protein of vesicular stomatitis virus (VSV) binds tightly to cellular membranes in vivo when expressed in the absence of other VSV proteins. This membrane-associated M protein was functional in binding purified VSV nucleocapsids in vitro. Here we show that the membrane-associated M protein is largely associated with a membrane fraction having the density of plasma membranes, indicating membrane specificity in the binding. In addition, we analyzed truncated forms of M protein to identify regions responsible for membrane association and nucleocapsid binding. Truncated M protein lacking the amino-terminal basic domain still associated with cellular membranes, although not as tightly as wild-type M protein, and could not bind nucleocapsids. In contrast, deletion of the carboxy-terminal 14 amino acids did not disrupt stable membrane association or nucleocapsid interaction. These results suggest that the amino terminus of M protein either interacts directly with membranes and nucleocapsids or stabilizes a conformation that is required for M protein to mediate both of these interactions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8254754      PMCID: PMC236304     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  In vitro synthesis of a unique RNA species by a T particle of vesicular stomatitis virus.

Authors:  S U Emerson; P M Dierks; J T Parsons
Journal:  J Virol       Date:  1977-09       Impact factor: 5.103

2.  Localization of the membrane-associated region of vesicular stomatitis virus M protein at the N terminus, using the hydrophobic, photoreactive probe 125I-TID.

Authors:  J Lenard; R Vanderoef
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

3.  Isolation of subcellular organelles.

Authors:  B Storrie; E A Madden
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

4.  Prevention of HIV-1 glycoprotein transport by soluble CD4 retained in the endoplasmic reticulum.

Authors:  L Buonocore; J K Rose
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

5.  Role of matrix protein in cytopathogenesis of vesicular stomatitis virus.

Authors:  D Blondel; G G Harmison; M Schubert
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

6.  Distribution of M protein and nucleocapsid protein of vesicular stomatitis virus in infected cell plasma membranes.

Authors:  B J McCreedy; D S Lyles
Journal:  Virus Res       Date:  1989-11       Impact factor: 3.303

7.  Glycoprotein cytoplasmic domain sequences required for rescue of a vesicular stomatitis virus glycoprotein mutant.

Authors:  M A Whitt; L Chong; J K Rose
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

8.  Sites of in vivo phosphorylation of vesicular stomatitis virus matrix protein.

Authors:  P E Kaptur; B J McCreedy; D S Lyles
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

9.  The M protein of vesicular stomatitis virus associates specifically with the basolateral membranes of polarized epithelial cells independently of the G protein.

Authors:  J E Bergmann; P J Fusco
Journal:  J Cell Biol       Date:  1988-11       Impact factor: 10.539

10.  Electrostatic and hydrophobic interactions of synapsin I and synapsin I fragments with phospholipid bilayers.

Authors:  F Benfenati; P Greengard; J Brunner; M Bähler
Journal:  J Cell Biol       Date:  1989-05       Impact factor: 10.539

View more
  30 in total

1.  The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly.

Authors:  C S Robison; M A Whitt
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus.

Authors:  A Ono; E O Freed
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity.

Authors:  R E Kiernan; A Ono; E O Freed
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

4.  Infectious hematopoietic necrosis virus matrix protein inhibits host-directed gene expression and induces morphological changes of apoptosis in cell cultures.

Authors:  P P Chiou; C H Kim; P Ormonde; J A Leong
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  Cellular membrane-binding ability of the C-terminal cytoplasmic domain of human immunodeficiency virus type 1 envelope transmembrane protein gp41.

Authors:  S S Chen; S F Lee; C T Wang
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  A confocal and electron microscopic comparison of interferon beta-induced changes in vesicular stomatitis virus infection of neuroblastoma and nonneuronal cells.

Authors:  Paul M D'Agostino; Carol Shoshkes Reiss
Journal:  DNA Cell Biol       Date:  2010-03       Impact factor: 3.311

Review 7.  Virus maturation by budding.

Authors:  H Garoff; R Hewson; D J Opstelten
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

8.  Crystal structure of the Borna disease virus matrix protein (BDV-M) reveals ssRNA binding properties.

Authors:  Piotr Neumann; Diana Lieber; Sylke Meyer; Philipp Dautel; Andreas Kerth; Ina Kraus; Wolfgang Garten; Milton T Stubbs
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

9.  IFN-beta-induced alteration of VSV protein phosphorylation in neuronal cells.

Authors:  Paul M D'agostino; Jessica J Amenta; Carol Shoshkes Reiss
Journal:  Viral Immunol       Date:  2009-12       Impact factor: 2.257

10.  Rabies virus M protein expressed in Escherichia coli and its regulatory role in virion-associated transcriptase activity.

Authors:  Y Ito; A Nishizono; K Mannen; K Hiramatsu; K Mifune
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.